EUVIMEDEUVIMED entdecken
Crossref

ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis

Miao Liu, Zhuowei Liu, Ying Leng, Qianru Zhang, Chengwu Liu, Yuqin Yao, Xiaoxin Chen

Biochemical and Biophysical Research Communications · 2026-11 · 839 · 154684

DOI: 10.1016/j.bbrc.2026.154684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-11. Verfasst von Miao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610041, China; Guangdong Raynovent Biotechnology, Gua…. Hauptthemen laut MEDLINE: Phosphodiesterase Inhibitors, Fatty Liver. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health challenge. Its advanced stage, metabolic dysfunction-associated steatohepatitis (MASH), involves complex processes such as metabolic dysregulation, inflammation, and fibrosis. Existing treatments mainly target steatosis but have limited success. Therefore, focusing on inflammation and fibrosis may offer more effective therapeutic options. Phosphodiesterases regulate cAMP/cGMP signaling and are key in MASH-related inflammation and fibrosis. Inhibiting specific PDE subtypes is a promising approach for drug development in MASH. This study presents a comprehensive preclinical pharmacological and pharmacokinetic profile of ZSP1601, a non-selective phosphodiesterase inhibitor currently in clinical trials for MASH. ZSP1601 was developed through structural optimization of pentoxifylline via a three-step chemical synthesis. Molecular docking and enzymatic assays confirmed its role as a non-selective PDE inhibitor. In vitro, ZSP1601 significantly lowered TNF-α levels, showed strong anti-inflammatory effects, and was more effective than pentoxifylline at the same dose. In vivo, ZSP1601 markedly reduced liver NAS scores in the STZ + HFD model and decreased fibrosis in the CDAHFD model in a dose-dependent manner. Consistent with these results, data from liver fibrosis models demonstrated that ZSP1601 significantly alleviated hepatocellular injury and reduced hepatic fibrosis. Pharmacokinetic studies indicated that ZSP1601 has favorable properties in mice, rats, and beagle dogs after single and multiple doses. In summary, ZSP1601, a non-selective PDE inhibitor, presents a promising new treatment for MASH by effectively improving disease outcomes. It is currently being evaluated in a phase II clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase InhibitorsFatty LiverAnimalsMaleAdministration, OralMiceTumor Necrosis Factor-alphaMolecular Docking SimulationHumansPentoxifyllineMice, Inbred C57BLLiver

Stichwörter der Autor:innen

FibrosisInflammationMASHPhosphodiesterase inhibitorTNF-αZSP1601

Substanzen

Phosphodiesterase InhibitorsTumor Necrosis Factor-alphaPentoxifylline

Autor:innen und Institutionen

  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610041, China; Guangdong Raynovent Biotechnology, Guangzhou, 510700, China.
  • Guangdong Raynovent Biotechnology, Guangzhou, 510700, China.
  • Hunan Pharmaceutical Development and Investment Group Co., Ltd., Changsha, 410002, China.
  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: yuqin_yao@scu.edu.cn.
  • Guangdong Raynovent Biotechnology, Guangzhou, 510700, China. Electronic address: chen_xiaoxin@raynovent.com.

Zitieren

APA

Liu, M., Liu, Z., Leng, Y., Zhang, Q., Liu, C., Yao, Y., & Chen, X. (2026). ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis. Biochemical and Biophysical Research Communications, 839, 154684. https://doi.org/10.1016/j.bbrc.2026.154684

Vancouver

Liu M, Liu Z, Leng Y, Zhang Q, Liu C, Yao Y, et al. ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis. Biochemical and Biophysical Research Communications. 2026;839:154684. doi:10.1016/j.bbrc.2026.154684

BibTeX
@article{Liu2026,
  author = {Liu, Miao and Liu, Zhuowei and Leng, Ying and Zhang, Qianru and Liu, Chengwu and Yao, Yuqin and Chen, Xiaoxin},
  title = {ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2026},
  volume = {839},
  pages = {154684},
  doi = {10.1016/j.bbrc.2026.154684}
}
Kostenlos starten →